NICE fails to endorse Roche's Tecentriq for breast cancer; Elicio closes financing round with $33M
→ UK’s cost-effectiveness watchdog NICE is not backing Roche‘s PD-L1 checkpoint inhibitor Tecentriq (known chemically as atezolizumab), in another blow to the Swiss drugmaker who revealed the drug wasn’t strong enough to score approval in bladder cancer at the ESMO conference last weekend. NICE’s draft guidance, however, pertains to the immunotherapy’s use in advanced breast cancer in combination with the chemotherapy nab-paclitaxel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.